Gain insights from TransMedics Group’s Q2 2025 earnings, highlighting 38% YoY revenue growth, raised full-year guidance, and innovation-driven future growth.

Kedrion Biopharma receives US FDA orphan drug designation for Coagadex to treat acquired Factor X deficiency: Fort Lee, New Jersey Thursday, July 31, 2025, 15:00 Hrs [IST] Kedrion ...

Trethera Corporation ('Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer ...

In early-phase drug development, the success of a dose escalation study depends not only on the design but also on the speed and accuracy of decision-making across cohorts. Delays in progressing ...

We spoke with endocrinologists to explore the potential of artificial intelligence in the management of chronic disease, including diabetes, obesity, and PCOS.

Discover key takeaways from Anika Therapeutics' Q2 2025 earnings call, including Hyalofast's trial updates, Integrity's strong growth, and ...

If included in National List of Essential Medicines (NLEM), the fixed-dose combinations (FDCs) to rein in hypertension can be ...

Fasting may have potential health benefits for some people, including weight loss, heart health, blood sugar control, brain ...

License agreement supports Madrigal's pipeline strategy to develop innovative combination treatments for MASH, anchored by its foundational therapy Rezdiffra (resmetirom) Combining Rezdiffra with the ...

NeuroScientific Biopharmaceuticals is banking on its new, well-credentialled Perth-based chief medical officer to help the company roll out its innovative stem cell therapy.